QNRX

Quoin Pharmaceuticals Ltd DRC

NASDAQ: QNRX · HEALTHCARE · BIOTECHNOLOGY

$4.15

+0.97% today

Updated 2026-10-29

Market cap

$19.31M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-5.67

Dividend yield

—

52W range

$3 – $24

Volume

0.7M

Market cap

$19.31M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-5.67

Dividend yield

—

52W range

$3 – $24

Volume

0.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.3

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-5.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →257 stocks currently score above 75

Price targets

Analyst target

$20.38

+391.08%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -5.50 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-3.21M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-9.38M	$-8.69M	$-8.96M	$-15.80M	$-5.46M
EPS	—	—	—	—	$-5.67
Free cash flow	$-8.73M	$-7.86M	$-7.86M	$-13.54M	$-3.21M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
QNRX	$19.31M	20	4.3	3.0	5.0	4.3	—	Avoid
LLY	$1.12T	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$615.87B	57	4.7	8.5	2.7	5.5	-83.05%	Buy
ABBV	$504.37B	73	6.7	8.5	4.0	5.0	-86.73%	Strong Buy
UNH	$360.32B	62	6.7	6.0	4.7	5.5	-25.92%	Buy
MRK	$360.08B	36	4.0	4.5	2.0	5.0	-73.68%	Hold

Smart narrative

Quoin Pharmaceuticals Ltd DRC trades at $4.15. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -5.50, it sits in the distress.

Frequently asked questions

What is Quoin Pharmaceuticals Ltd DRC's stock price?

Quoin Pharmaceuticals Ltd DRC (QNRX) trades at $4.15.

Is Quoin Pharmaceuticals Ltd DRC overvalued?

Quoin Pharmaceuticals Ltd DRC carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Quoin Pharmaceuticals Ltd DRC (QNRX)?

The 12-month analyst consensus target is $20.38, about 391.1% above the current $4.15. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Quoin Pharmaceuticals Ltd DRC's Altman Z-Score is -5.50, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-193.51%

Beta1.75

50D MA$5.51

200D MA$6.24

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

QNRX vs LLY →QNRX vs JNJ →QNRX vs ABBV →Stock screener →